Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IB study of MK-3475 in PD-L1-positive advanced solid tumors
NL-OMON47029Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2014
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in advanced nonhematological malignancy, colorectal adenocarcinoma, anal squamous cell carcinoma (SCCA) and 20 more, sponsored by Merck & Co. Primary endpoint: Preliminary antitumor activity by RECIST 1.1. Started Apr 2014; status: active, not recruiting.
02
Drugs
03
Conditions
advanced nonhematological malignancycolorectal adenocarcinomaanal squamous cell carcinoma (SCCA)pancreatic adenocarcinoma (PDAC)esophageal cancer
Beyond the preview
Go deeper on NL-OMON47029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47029.